



OFFICERS

Cynthia Jean Goto, MD
President

Gary Okamoto, MD
President Elect

Linda Rasmussen, MD
Immediate Past President

Thomas Kosasa, MD
Secretary

Jonathan Cho, MD
Treasurer

Paula Arcena
Executive Director

April 1, 2008

To: Rep. Tommy Waters, Chair
Rep. Blake K. Oshiro, Vice Chair
Judiciary Committee

Rep. Jerry L. Chang, Chair
Rep. Joe Bertram III, Vice Chair
Higher Education Committee

From: Cynthia J. Goto, M.D., President
Linda Rasmussen, M.D., Legislative Co-Chair
Philip Hellreich, M.D., Legislative Co-Chair
Paula Arcena, Executive Director
Dick Botti, Government Affairs Liaison

Re: SB2040 SD1, HD1 Relating to Cancer Surveillance (Allows a cancer patient to be contacted directly without initial physician contact for purposes of cancer surveillance. Adds pre-cancer to diseases about which data are authorized for collection. Adds biological specimens to the materials that may be collected to assist cancer research.)

The Hawaii Medical Association supports SB2040 SD1, HD1.

The HMA has worked with representatives of the University of Hawaii, Department of Health and Kaiser Permanente to identify amendments to the bill. We support the amendments submitted by the University of Hawaii.

We respectfully request the committee accept these suggested amendments.

Thank you for the opportunity to testify on this matter.

PLEASE DELIVER
Judiciary COMMITTEE

Tuesday
4/1/2008
2:00pm
Room 325

Hawaii Medical Association
1360 S. Beretania St.
Suite 200
Honolulu, HI 96814
(808) 536-7702
(808) 528-2376 fax
www.hmaonline.net

000010

Testimony of
Phyllis Dendle
Director of Government Affairs

Before:
House Committee on Judiciary
The Honorable Tommy Waters, Chair
The Honorable Blake Oshiro, Vice Chair

April 1, 2008
2:00 pm
Conference Room 325

SB 2040 SD1 HD1**RELATING TO CANCER SURVEILLANCE**

Chair Waters and committee members, thank you for this opportunity to provide testimony on SB 2040 SD1 HD1 which amends the law regarding the Hawaii Tumor Registry.

Kaiser Permanente supports this bill.

This version of the bill represents the work of numerous interested parties. The UH Cancer Research Center, Hawaii Medical Association, Department of Health and Kaiser Permanente Hawaii all have worked to make this a good bill.

The bill will permit greater flexibility in the collection of information for cancer research and will also provide continued careful oversight of the use of this information.

We encourage you to pass it in its current form.

Thank you for your consideration.

711 Kapiolani Blvd
Honolulu, Hawaii 96813
Telephone: 808-432-5210
Facsimile: 808-432-5906
Mobile: 808-754-7007
E-mail: phyllis.dendle@kp.org

C00011



UNIVERSITY OF HAWAII SYSTEM

Legislative Testimony

Testimony Presented Before the House Committee on Judiciary

April 1, 2008 at 2:00 p.m.

by

Virginia S. Hinshaw, Chancellor

and

Carl-Wilhelm Vogel, MD, PhD

Director, Cancer Research Center of Hawai'i

University of Hawai'i at Mānoa

SB 2040 SD1 HD1– RELATING TO CANCER SURVEILLANCE

Chair Waters, Vice Chair Oshiro, Members of the House Committee on Judiciary:

The University of Hawai'i strongly supports S.B. No. 2040 SD1, HD1, Relating to Cancer Surveillance, which would help us to achieve the goals of Hawaii Comprehensive Cancer Control Consortium (HCCCC), namely to save lives and improve the quality of life for individuals affected by cancer. First, the revised statute would give Hawai'i citizens the right to choose whether or not they wish to participate in cancer research studies. Presently, physician permission is required in Hawai'i before individual contact can be made. The requirement for physician permission preempts our citizens' ability to make personal decisions about their healthcare and limits their accrual to beneficial cancer research.

The second obstacle to achieving the goals of the HCCCC Plan is the ambiguous meaning of 'data or relevant material' that is part of the statute. The Hawaii Tumor Registry currently collects tissue and other biological specimens from cancer patients as part of its activities. It is important that the statute be clarified in this regard, providing the Tumor Registry with the authority to collect and house biological specimens that might be used in de-identified/anonymized research.

Finally, although information on pre-cancerous lesions has been collected by the HTR in the past (e.g., cervical dysplasia), specific statutory authority to do so is unclear. Collection of information on individuals with pre-cancerous disease is an important means to monitor cancer screening activities (e.g., prostate cancer screening) or to monitor the efficacy of cancer vaccines, such as the newly introduced vaccine against the human papillomavirus.

We therefore advocate these minor revisions to H.R.S. § 324-21 and 321-29 to 1) increase community participation in research studies; 2) increase the research utility of the Hawaii Tumor Registry; 3) allow comprehensive monitoring of the efficacy of cancer screening and cancer vaccination activities; 4) enhance the quality of life of cancer survivors; and 5) stimulate community awareness of the Cancer Information Service and local community cancer prevention efforts. We urge the Committee to pass S.B. No. 2040. Thank you for this opportunity to testify.

C00012